about
Micro-NMR for rapid molecular analysis of human tumor samplesTranscriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern ChinaIdentifying potential indicators to measure the outcome of translational cancer research: a mixed methods approachLarge-scale integration of cancer microarray data identifies a robust common cancer signature.Genomic and oncoproteomic advances in detection and treatment of colorectal cancerImmunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains.Robust automated tumour segmentation on histological and immunohistochemical tissue images.Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.An in vivo platform for tumor biomarker assessment.The implications of biomarker evidence for systematic reviews.Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma.Science behind human saliva.Biomarker method validation in anticancer drug developmentMethod validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro.Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for diseaseAcute Kidney Injury Biomarkers - Needs, Present Status, and Future PromisePredictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma.Searching for 'omic' biomarkersAn expression signature at diagnosis to estimate prostate cancer patients' overall survivalDevelopment and validation of H11B2C2 monoclonal antibody-reactive hyaluronic acid binding protein: overexpression of HABP during human tumor progression.Quantitative analysis of p53 expression in human normal and cancer tissue microarray with global normalization method.Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.What will it take to obtain DNA methylation markers for early cervical cancer detection?The Athena Breast Health Network: developing a rapid learning system in breast cancer prevention, screening, treatment, and care.The US Food and Drug Administration perspective on cancer biomarker development.Combining multiple biomarker models in logistic regression.Aptamers and Their Significant Role in Cancer Therapy and Diagnosis.Up-regulation of inflammation-related LncRNA-IL7R predicts poor clinical outcome in patients with cervical cancer.Aptamers: novelty tools for cancer biology.Human tissue biobanks as instruments for drug discovery and development: impact on personalized medicineDisease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma
P2860
Q24603587-35AF660F-9771-4A61-AFD2-3BA186786A22Q24647880-48347B21-BF3B-4823-9D93-509493BEBBE6Q27303882-51738992-8773-426B-A3A7-E268778C2F90Q31120275-3459367F-7B65-4BE3-B222-5F04C7A69334Q33425477-55A180C4-0370-43BE-862C-8C499D0920A2Q33529063-C0A5418B-81DD-4045-BF5F-3CE138841B44Q33840806-60F9B430-E819-4778-8B2F-7C1E603559BBQ33847836-E4714AC4-25A3-4991-A801-0F926B1F630CQ34064633-11599316-D458-4EC6-A1BB-A08A478DFEC0Q34485871-6DE3B524-C45D-4606-92B2-57EC5C760E3CQ35633563-970B1764-4C42-49F5-88D4-57EDD40F550AQ35853848-1DEB930B-D801-4D7C-8D3C-00D5A22C3021Q36484621-3ACB6FAE-59AC-4941-BEA3-0FFB31C15030Q36611534-5CC71387-B3CC-40A8-92D8-D6BCF0036C69Q36625832-F0E82599-D97A-48B5-BDCF-F2490D9793A6Q36816034-97896DE6-354D-41BE-B5E2-5594EBD11599Q36981219-E95341C1-EE84-41A7-8240-D0C8AF9B4DCFQ37016752-B2C59ED1-4A77-4F60-8E8F-0B9E4E7B8DE2Q37328373-D8868CF0-CD39-45CC-A042-FAD586B0BE6CQ37461802-7D5C16B7-08C4-408C-8BCD-F33611E71FA5Q37517240-6D54BE16-D679-413B-B487-088895B67669Q37578965-6553099A-63F5-4C7D-8C90-5040F7F2A367Q38320495-17946773-8937-49EE-BE5A-659C8AE81E4BQ39990401-8871B77C-505F-47FE-9B80-318A254F1979Q40076929-246442E0-BC2D-448C-86D2-FE8E3824B331Q43156191-C4DD30B1-6437-42F7-80E8-6C9E7360E77BQ46033349-19A6F59A-CE12-4B67-916D-3DCC948E74E9Q51174629-2A8370EA-9F43-4DB3-B2BF-4DF43380A083Q51891478-6ADC369A-3077-4B59-91AC-C65F1BF50689Q54457076-00407554-2479-42AC-960C-7EC441807DA0Q55086619-E144BD3E-52B9-4264-A83E-C9AFF2C2749EQ55285633-03D87717-2E5F-44F5-A0DE-054C507A5DDEQ56778489-09FADA7D-9851-45C2-8780-5761006B4194Q57941761-7D16DACC-EC6C-4350-942F-E87D3FFF7B64
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Translational crossroads for biomarkers.
@ast
Translational crossroads for biomarkers.
@en
type
label
Translational crossroads for biomarkers.
@ast
Translational crossroads for biomarkers.
@en
prefLabel
Translational crossroads for biomarkers.
@ast
Translational crossroads for biomarkers.
@en
P2093
P50
P1476
Translational crossroads for biomarkers.
@en
P2093
Andrew Allen
Andrew Hruszkewycz
David L Rimm
George Klee
Herbert Fritsche
Nicole Urban
Robert Veltri
Steven Gutman
P304
P356
10.1158/1078-0432.CCR-04-2213
P407
P577
2005-09-01T00:00:00Z